Moreover, these data provide evidence in support of clinical trials investigating short courses of anti-CD3/DPP-4 inhibitor combination therapy given early in the course of type 1 diabetes with the purpose of inducing long-lasting disease remission. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.